

**Western Equine Encephalitis Virus,
CO921356**

Catalog No. NR-41569

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Scott C. Weaver, Ph.D., Director, Institute for Human Infections and Immunity, and Scientific Director, Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA

Manufacturer:

BEI Resources

Product Description:

Virus Classification: *Togaviridae, Alphavirus*

Species: Western equine encephalitis virus

Strain/Isolate: CO921356

Comments: Western equine encephalitis virus (WEEV), CO921356 was isolated in Vero cells from a pool of *Culex tarsalis* (*C. tarsalis*) mosquitoes collected in Larimer City, Colorado, USA on July 30, 1992.^{1,2} The complete genome sequence of WEEV, CO921356 has been determined (GenBank: [KJ554979](https://www.ncbi.nlm.nih.gov/nuccore/KJ554979)).

WEEV is a mosquito-borne alphavirus that causes potentially fatal infections in horses and humans.^{3,4} Survivors of western equine encephalitis (WEE) often suffer permanent neurological sequelae. WEEV circulates enzootically among passerine birds and is transmitted primarily by *C. tarsalis*, with mammals participating in a secondary cycle. Humans and horses do not appear to be amplifying hosts.

WEEV is the descendent of an ancient recombination event between Sindbis virus-like and eastern equine encephalitis virus-like progenitors.^{5,6} There were widespread outbreaks of WEE in western North America in the 1930s through 1950s, but the incidence of the disease has decreased dramatically in recent decades. This reduction in disease incidence has been accompanied by a decline in the frequency of virus detection in mosquito surveillance programs.⁷

Material Provided:

Each vial contains approximately 1 mL of cell lysate and supernatant from *Aedes albopictus* mosquito larval epithelial cells (clone C6/36; ATCC® CRL-1660™) infected with WEEV, CO921356.

Packaging/Storage:

NR-41569 was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen and should be

stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Western Equine Encephalitis Virus, CO921356, NR-41569.”

Biosafety Level: 3

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Bergren, N. A., et al. "Western Equine Encephalitis Virus: Evolutionary Analysis of a Declining Alphavirus Based on Complete Genome Sequences." J. Virol. 88 (2014): 9260-9267. PubMed: 24899192.
2. Weaver, S. C., Personal Communication.
3. Whitley, R. J., and J. W. Gnann. "Viral Encephalitis: Familiar Infections and Emerging Pathogens." Lancet 359 (2002): 507-513. PubMed: 11853816.
4. Centers for Disease Control and Prevention. "Arboviral Disease – United States, 1994." MMWR Morb. Mortal. Wkly. Rep. 44 (1995): 641-644. PubMed: 7643850.
5. Hahn, C. S., et al. "Western Equine Encephalitis Virus is a Recombinant Virus." Proc. Soc. Natl. Acad. Sci. USA 85 (1988): 5997-6001. PubMed: 3413072.
6. Weaver, S. C., et al. "Recombinational History and Molecular Evolution of Western Equine Encephalomyelitis Complex Alphaviruses." J. Virol. 71 (1997): 613-623. PubMed: 8985391.
7. Zhang, M., et al. "Variation in Western Equine Encephalomyelitis Viral Strain Growth in Mammalian, Avian, and Mosquito Cells Fails to Explain Temporal Changes in Enzootic and Epidemic Activity in California." Vector-Borne Zoonotic Dis. 11 (2011): 269-275. PubMed: 21395409.

ATCC® is a trademark of the American Type Culture Collection.

